Mimedx (MDXG) EBITDA (2011 - 2026)

Mimedx has disclosed EBITDA across 16 years of filings, most recently posting -$16.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$16.0 million, down 294.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.6 million (down 26.58% YoY), and the FY2025 annual result was $63.9 million, up 8.53% from the prior year.
• EBITDA came in at -$16.0 million for Q1 2026 at Mimedx, down from $21.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $23.4 million in Q2 2024 to a low of -$16.0 million in Q1 2026.
• The 5-year median for EBITDA is $11.1 million (2023), against an average of $7.6 million.
• Across the five-year window, EBITDA tumbled 2250.24% in 2022 and jumped 3981.76% in 2024, its largest moves.
• Mimedx's EBITDA stood at $11.3 million in 2022, then jumped by 36.95% to $15.5 million in 2023, then decreased by 28.64% to $11.1 million in 2024, then surged by 90.67% to $21.1 million in 2025, then plunged by 176.14% to -$16.0 million in 2026.
• The last three EBITDA figures came in at -$16.0 million (Q1 2026), $21.1 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.